KRYS Stock Overview
A commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Krystal Biotech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$208.55 |
52 Week High | US$214.98 |
52 Week Low | US$93.95 |
Beta | 0.84 |
11 Month Change | 17.31% |
3 Month Change | 22.94% |
1 Year Change | 61.84% |
33 Year Change | 231.61% |
5 Year Change | 326.66% |
Change since IPO | 1,860.06% |
Recent News & Updates
Recent updates
Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Krystal Biotech EPS misses by $0.16
May 10Krystal Biotech provides update on pivotal GEM-3 study of B-VEC for DEB
Apr 26Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Mar 02Krystal Biotech secures $125 capital via equity raise
Feb 03Shareholder Returns
KRYS | US Biotechs | US Market | |
---|---|---|---|
7D | 7.7% | 5.0% | 2.2% |
1Y | 61.8% | 15.2% | 22.6% |
Return vs Industry: KRYS exceeded the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: KRYS exceeded the US Market which returned 22% over the past year.
Price Volatility
KRYS volatility | |
---|---|
KRYS Average Weekly Movement | 5.1% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: KRYS's share price has been volatile over the past 3 months.
Volatility Over Time: KRYS's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 229 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
KRYS fundamental statistics | |
---|---|
Market cap | US$5.94b |
Earnings (TTM) | US$57.16m |
Revenue (TTM) | US$95.95m |
104.2x
P/E Ratio62.1x
P/S RatioIs KRYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
KRYS income statement (TTM) | |
---|---|
Revenue | US$95.95m |
Cost of Revenue | US$5.51m |
Gross Profit | US$90.44m |
Other Expenses | US$33.28m |
Earnings | US$57.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.00 |
Gross Margin | 94.25% |
Net Profit Margin | 59.57% |
Debt/Equity Ratio | 0% |
How did KRYS perform over the long term?
See historical performance and comparison